Pharma Commercial Mock

← All views·CI feed·API docs

ASCO

Meeting Library

AACR Annual Meeting 2026 · San Diego, CA

Abstract 61442026-04-05 · 14:15 CT · S100A
Quality of life outcomes with Keytruda in patients with RCC
R. Herbst, T. Mok, S. Modi, et al. · Massachusetts General Hospital
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 68222026-04-05 · 19:00 CT · Hall B1
Real-world effectiveness of Keytruda vs standard of care in RCC
F. Andre, S. Antonia · University of Chicago
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 63172026-04-03 · 13:30 CT · S100A
Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-796
J. Brahmer, L. Paz-Ares · Institut Gustave Roussy
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 67152026-04-05 · 18:00 CT · S100A
Quality of life outcomes with Opdivo in patients with RCC
A. Spira, J. Cortes · Memorial Sloan Kettering Cancer Center
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 63432026-04-04 · 21:45 CT · S100A
CheckMate-649: Opdivo (nivolumab) 3L+ in RCC
L. Paz-Ares, M. Krop · Cleveland Clinic
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 60552026-04-04 · 19:30 CT · Arie Crown Theater
Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-803
N. Rizvi, C. Saura, M. Krop, et al. · Princess Margaret Cancer Centre
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 68562026-04-02 · 15:15 CT · E450
Long-term follow-up of Opdivo maintenance for RCC: CheckMate-628
S. Tolaney, H. Borghaei, M. Reck, et al. · Peter MacCallum Cancer Centre
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 60812026-04-05 · 16:00 CT · E450
Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-909
S. Antonia, P. Schmid, F. Andre, et al. · Chinese University of Hong Kong
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 62282026-04-04 · 13:45 CT · E450
Real-world effectiveness of Opdivo vs standard of care in RCC
E. Winer, R. Herbst, C. Saura, et al. · Princess Margaret Cancer Centre
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 69132026-04-05 · 14:45 CT · Arie Crown Theater
KEYNOTE-190: Keytruda (pembrolizumab) 3L+ in RCC
F. Andre, S. Modi · UCSF Helen Diller Family Comprehensive Cancer Center
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 60922026-04-02 · 15:15 CT · Arie Crown Theater
Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-763
P. Schmid, A. Spira, S. Peters, et al. · Stanford Cancer Institute
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 68842026-04-02 · 14:00 CT · S406
Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-298
M.C. Garassino, C. Saura, H. Borghaei, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 64132026-04-04 · 13:00 CT · S100A
Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-807
C. Robert, G. Curigliano · Cleveland Clinic
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 63752026-04-05 · 21:45 CT · S100A
CheckMate-516: Opdivo (nivolumab) 1L in RCC
H. Borghaei, L. Paz-Ares · University of Chicago
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 66002026-04-03 · 20:00 CT · Arie Crown Theater
Long-term follow-up of Opdivo 1L for RCC: CheckMate-325
A. Spira, C. Saura, R. Herbst, et al. · Dana-Farber Cancer Institute
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 63202026-04-05 · 14:00 CT · E450
Long-term follow-up of Keytruda 2L for RCC: KEYNOTE-237
H. Rugo, M. Reck, F. Andre · Stanford Cancer Institute
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 65152026-04-02 · 13:15 CT · Hall B1
Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-340
N. Rizvi, F. Andre, E. Winer · Cleveland Clinic
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 67142026-04-01 · 14:45 CT · Arie Crown Theater
KEYNOTE-17: Keytruda (pembrolizumab) neoadjuvant in RCC
J. Cortes, N. Rizvi, S. Modi · National Cancer Center Japan
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 69962026-04-01 · 16:30 CT · S100A
CheckMate-901: Opdivo (nivolumab) 1L in RCC
P. Schmid, H. Borghaei, M. Krop · UCSF Helen Diller Family Comprehensive Cancer Center
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 60802026-04-01 · 18:45 CT · Arie Crown Theater
Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-645 study)
S. Tolaney, M.C. Garassino, A. Spira, et al. · Cleveland Clinic
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 63492026-04-02 · 21:15 CT · Hall B1
Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-173
F. Andre, S. Tolaney, T. Mok, et al. · Karolinska Institute
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 64612026-04-03 · 16:15 CT · S100A
Long-term follow-up of Keytruda 3L+ for RCC: KEYNOTE-221
R. Herbst, T. Mok, J. Cortes, et al. · Princess Margaret Cancer Centre
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 67662026-04-03 · 20:45 CT · S406
Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-575
J. Cortes, C. Saura · Stanford Cancer Institute
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 67092026-04-01 · 20:45 CT · S100A
Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-64 study)
F. Andre, A. Spira, R. Herbst, et al. · Karolinska Institute
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 61122026-04-05 · 19:30 CT · Arie Crown Theater
Long-term follow-up of Keytruda neoadjuvant for RCC: KEYNOTE-981
J. Cortes, L. Paz-Ares, N. Rizvi, et al. · Princess Margaret Cancer Centre
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 62582026-04-02 · 16:30 CT · Arie Crown Theater
CheckMate-518: Opdivo (nivolumab) maintenance in RCC
S. Peters, R. Herbst · Stanford Cancer Institute
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract 69662026-04-04 · 19:00 CT · Arie Crown Theater
CheckMate-616: Opdivo (nivolumab) maintenance in RCC
S. Antonia, F. Andre, S. Modi, et al. · Institut Gustave Roussy
Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️

Abstract 6144

Quality of life outcomes with Keytruda in patients with RCC

R. Herbst¹, T. Mok, S. Modi, H. Rugo

¹ Massachusetts General Hospital (presenter)

Poster Discussion Session: Genitourinary Cancer—Kidney/Bladder[view all in session]

2026-04-05 · 14:15 CT · S100A · Sponsor: Merck

Background: Despite the availability of immune checkpoint inhibitors, optimal first-line therapy for RCC remains an open question. Keytruda (undefined) is a anti-PD-1 mAb.

Methods: III-phase, randomized trial (KEYNOTE-856, NCT96691104). Patients with RCC were randomized to Keytruda or placebo + chemotherapy. Primary endpoint: overall survival.

Results: OS 50.2 months (HR 0.92, 95% CI 0.81-0.99, p0.08). PFS 22.9 months. ORR 55%.

Conclusions: Median OS 50.2 months. HR 0.92 (95% CI 0.81–0.99). No new safety signals identified.

Clinical trial information: NCT96691104

Citation: J Clin Oncol 44, 2026 (suppl 17; abstr 6144). DOI: 10.1200/JCO.2026.44.17_suppl.6144

▸ Author disclosures

R. Herbst: Consulting/advisory — Merck; Research funding (institution) — Merck.